Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
The short answer for operators
Federal regulators (the DOL’s Employee Benefits Security Administration, HHS/CMS, and the U.S. Department of the Treasury) are actively enforcing MHPAEA parity against payers for FDA-approved medications for opioid use disorder, and treatment operators who audit payer NQTL comparative analyses, prior authorization patterns, and denial data right now can convert payer non-compliance into stronger contract terms before enforcement actions blow up reimbursement. This is not a theoretical shift. EBSA has primary MHPAEA enforcement jurisdiction over roughly 2.6 million health plans covering about 136 million workers, retirees and their families, and the tri-agency 2024 Report to Congress made clear the agencies are still pulling comparative analyses apart line by line.
What operators need to internalize: when a contracted payer is out of parity on buprenorphine, methadone, or naltrexone, the operator absorbs the practical downside. Denied claims. Retroactive UM changes. Members bounced off MAT mid-episode. The window to renegotiate UM protocols, single-case agreement terms, and rate structures opens when the operator walks into the payer meeting with a documented pattern of NQTL disparity, not after EBSA issues a determination letter.
What the enforcement data actually shows
The numbers from the January 2025 tri-agency report are worth reading twice. Since the CAA’s changes to MHPAEA took effect in February 2021, EBSA has requested and reviewed comparative analyses for hundreds of NQTLs and obtained corrections that removed impermissible MH/SUD treatment barriers for more than 7.6 million participants in over 72,000 plans. EBSA is currently devoting nearly 25 percent of its enforcement program to MHPAEA NQTL work. That is not a rounding error inside a federal agency. That is a strategic allocation.
On the CMS side, the story is similar but smaller in scale. During the CMS reporting period between September 2, 2022 and July 31, 2023, CMS issued 22 letters requesting comparative analyses, 10 insufficiency letters, 19 initial determination letters finding MHPAEA NQTL violations, and 3 final determination letters of noncompliance. CMS is running that program with roughly 15 investigators covering about 91,000 non-federal governmental plans and 67 issuers in Texas and Wyoming, the two states where CMS is the direct enforcer. Thin staffing, high hit rate. Read that as: the agencies are picking their targets carefully, and the targets are losing.
The 2024 Final Rule (published in the Federal Register on September 23, 2024) added content requirements and timeframes to the comparative analysis obligation. Enforcement of the new portions of that rule is paused pending ERIC litigation, but the Departments note that MHPAEA’s statutory obligations, as amended by the CAA, 2021, continue to have effect. Translation for operators: the underlying parity duty and the comparative-analysis mandate did not go away. Only the newer rule mechanics are on hold.
Where MAT gets squeezed, and what to audit
The MAT-specific problem is well documented. Buprenorphine decreases opioid-related mortality risk by 50 percent, yet commercial plans have historically wrapped it in prior authorization, quantity limits, fail-first requirements, and mandatory counseling attestations that no comparable medical/surgical prescription faces. The Weill Cornell team recently published in JAMA Health Forum that only 30.4 percent of privately insured patients stayed on buprenorphine for at least 180 days without gaps exceeding seven days, even as 19 states banned prior authorization on the drug. Why? Residual utilization-management requirements, including insurer-mandated toxicology testing, counseling, and quantity limits, likely offset administrative gains, while limited transparency hampers state monitoring and enforcement of private-plan compliance.
That last sentence is the operator opportunity. Payers moved the parity violation from the pharmacy PA line into a thicket of process NQTLs. Operators running SUD programs in Florida, South Carolina, Texas, and Ohio can see those NQTLs in their own claims data. Here is a working audit list:
- Prior authorization frequency and turnaround. Pull 12 months of PA requests for buprenorphine and naltrexone extended-release injection. Compare denial rates and turnaround times to PA on comparable specialty medical/surgical drugs under the same plan.
- Concurrent review triggers. Document how quickly the payer flips a residential or ASAM Level 3.7 residential withdrawal management stay into concurrent review versus a medical/surgical inpatient admission.
- Step therapy and fail-first. Pull every plan document that requires a patient to fail naltrexone before authorizing buprenorphine, or vice versa. That is a textbook NQTL that must have a documented comparative analysis behind it.
- Toxicology and counseling attestation requirements. These are process NQTLs. If the payer does not require analogous compliance attestations on medical/surgical drug classes, that gap is your opening at the negotiating table.
- Out-of-network reimbursement methodology. The 2024 Final Rule expressly names OON rate methodology as an NQTL. Compare your MAT-adjacent OON allowables to comparable medical/surgical allowables in the same plan.
The clean claim rate and denial rate on your MAT and MOUD claims are the fastest indicators. If your denial rate on buprenorphine-adjacent claims is 3x your denial rate on comparable medical claims from the same payer, the operator has documentary evidence that a comparative analysis probably will not survive an EBSA request.
Turning the audit into contract wins
Sariah and Allison were on the ground in South Carolina in May 2026 for the Joint Commission survey supporting Coastal Recovery Center, and the pattern we see across the AHS book (five facilities across three states accredited by TJC that same month) is consistent: the operators with the cleanest claims data are the ones who walk into payer meetings holding the strongest hand. Parity data is the same tool, aimed at a different target.
A quote worth pinning above the contracting desk. Arnall Golden Gregory’s employee benefits group wrote in June 2026 that “MHPAEA comparative-analysis enforcement remains active” and that DOL and CMS continue issuing requests, insufficiency findings, and noncompliance determinations involving network adequacy, prior authorization, reimbursement methodologies, and other access-to-care barriers. Read that as a shopping list for what to include in your next payer memo.
Concrete moves the payer strategy team should make in the next 90 days:
- Request the payer’s NQTL comparative analysis in writing. Under the CAA, plans must make comparative analyses available on request to the Departments and applicable state authorities. Providers do not have the same statutory right, but a formal request creates a record and often surfaces gaps. Copy the state insurance commissioner if the payer stalls.
- Attach parity language to every contract renewal. Rate sheet negotiations should include a clause requiring the payer to represent that its UM protocols on MOUD are supported by a current comparative analysis. If the payer refuses, that refusal is itself informative.
- Feed the denial pattern to the state. State insurance commissioners and the NAIC parity workgroup coordinate with EBSA. Operator-filed complaints are one of the most common triggers for federal review.
- Escalate ERISA fiduciary exposure for self-funded plans. The 2024 Final Rule requires a named plan fiduciary to certify a prudent process. When a self-funded employer is your patient’s plan sponsor, that fiduciary is personally on the hook. Operators who explain this to HR benefits leaders at large regional employers often see faster resolution than through the TPA.
None of this requires litigation. It requires the operator’s revenue integrity team and contracting lead to work off the same data set, and to time the outreach around renewal cycles and the payer’s own compliance calendar.
Frequently asked questions
What NQTLs most frequently trigger MHPAEA violations for addiction medications?
The tri-agency reports repeatedly flag prior authorization scope, step therapy and fail-first, concurrent review intensity, network composition and reimbursement methodology, and blanket exclusions of methadone or specific buprenorphine formulations. The Final Rule names each of these categories explicitly. If the payer applies any of them to MOUD but not to comparable medical/surgical drug classes, a comparative analysis is required and often absent.
How can a treatment operator document payer parity non-compliance to support contract renegotiation?
Pull 12 to 24 months of claims data segmented by CPT/HCPCS and drug code. Calculate denial rate, days in AR, and prior authorization turnaround for MOUD lines and for comparable medical/surgical lines under the same plan. Save every denial letter, UM correspondence, and appeal outcome. Package the disparity into a one-page brief and bring it to the payer relations meeting before renewal.
Does MHPAEA apply to Medicaid managed care plans covering MOUD?
Yes. Medicaid MCOs, Medicaid alternative benefit plans, and CHIP plans are subject to MHPAEA through separate CMS regulations. State Medicaid agencies enforce, with CMS oversight. If your Florida or Ohio Medicaid MCO is imposing PA on buprenorphine that it does not impose on comparable medical/surgical drugs, the state Medicaid parity contact and CMS are both proper escalation points.
What claims data patterns suggest a payer is violating parity on buprenorphine or methadone coverage?
Watch for MOUD denial rates that run materially higher than medical/surgical denial rates from the same payer, PA turnaround times that exceed the payer’s stated SLA specifically for MOUD, concurrent review requests that hit MOUD claims at a rate disproportionate to comparable medical admissions, and OON allowables that come in below CMS or Medicare benchmarks for the same drug. Any one of these on its own is a question. Two or more is a pattern.
How should operators respond when a payer denies MAT based on ‘medical necessity’ inconsistently with medical/surgical benefits?
Appeal every one, and appeal on parity grounds, not just clinical grounds. Cite the plan’s obligation under MHPAEA and the CAA to apply medical necessity criteria to MH/SUD benefits no more stringently than to medical/surgical benefits. Request the plan’s written medical necessity criteria for MOUD and for a comparable medical/surgical drug class. If the payer refuses or the criteria differ materially, that refusal is itself evidence for the state and EBSA.
References
- DOL, HHS, Treasury: 2024 MHPAEA Report to Congress (January 2025)
- CMS-hosted copy of the 2024 MHPAEA Report to Congress
- Federal Register: Requirements Related to the Mental Health Parity and Addiction Equity Act (Final Rule, September 23, 2024)
- DOL/HHS/Treasury Statement on Enforcement of the 2024 MHPAEA Final Rule
- CMS: Mental Health Parity and Addiction Equity Act overview
- Nguyen et al., JAMA Health Forum: Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021
- Weill Cornell Medicine: Prior Authorization Bans for Buprenorphine Alone May Not Improve Treatment Retention (March 2026)
- Arnall Golden Gregory: DOL Signals Continued MHPAEA Enforcement Amid Rulemaking Reset (June 2026)
- MACPAC: Prior Authorization in Medicaid (August 2024)